JP2024535432A - Ｐｃｄｈ１９関連障害の治療のための組成物及び方法 - Google Patents

Ｐｃｄｈ１９関連障害の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2024535432A
JP2024535432A JP2024519062A JP2024519062A JP2024535432A JP 2024535432 A JP2024535432 A JP 2024535432A JP 2024519062 A JP2024519062 A JP 2024519062A JP 2024519062 A JP2024519062 A JP 2024519062A JP 2024535432 A JP2024535432 A JP 2024535432A
Authority
JP
Japan
Prior art keywords
pcdh19
oligonucleotide
oligonucleotides
nucleosides
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535432A5 (https=
Inventor
ペトロー スティーブン
Original Assignee
ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス filed Critical ザ フローリー インスティテュート オブ ニューロサイエンス アンド メンタル ヘルス
Publication of JP2024535432A publication Critical patent/JP2024535432A/ja
Publication of JP2024535432A5 publication Critical patent/JP2024535432A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024519062A 2021-09-27 2022-09-27 Ｐｃｄｈ１９関連障害の治療のための組成物及び方法 Pending JP2024535432A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163248803P 2021-09-27 2021-09-27
US63/248,803 2021-09-27
US202263333840P 2022-04-22 2022-04-22
US63/333,840 2022-04-22
PCT/AU2022/051153 WO2023044545A1 (en) 2021-09-27 2022-09-27 Compositions and methods for the treatment of pcdh19 related disorders

Publications (2)

Publication Number Publication Date
JP2024535432A true JP2024535432A (ja) 2024-09-30
JP2024535432A5 JP2024535432A5 (https=) 2025-10-29

Family

ID=85719092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519062A Pending JP2024535432A (ja) 2021-09-27 2022-09-27 Ｐｃｄｈ１９関連障害の治療のための組成物及び方法

Country Status (12)

Country Link
US (1) US20250002912A1 (https=)
EP (1) EP4408532A4 (https=)
JP (1) JP2024535432A (https=)
KR (1) KR20240068067A (https=)
AU (1) AU2022351990A1 (https=)
CA (1) CA3232862A1 (https=)
CL (1) CL2024000853A1 (https=)
CO (1) CO2024004737A2 (https=)
IL (1) IL311581A (https=)
MX (1) MX2024003947A (https=)
PE (1) PE20250738A1 (https=)
WO (1) WO2023044545A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024206668A1 (en) * 2023-03-31 2024-10-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic strategy for pcdh19-related encephalopathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5624892B2 (ja) * 2008-01-04 2014-11-12 セントラル アデレード ローカル ヘルス ネットワーク インコーポレイテッド Ｅｆｍｒ（女性に限られた癲癇及び精神遅滞）の診断方法及び治療方法
EP3118326B1 (en) * 2008-10-27 2020-04-29 Sapporo Medical University Molecular marker for cancer stem cell
US9562892B2 (en) * 2012-10-02 2017-02-07 New York University Methods and agents for modulating protocadherin-18 activity
WO2020191233A1 (en) * 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences

Also Published As

Publication number Publication date
EP4408532A1 (en) 2024-08-07
PE20250738A1 (es) 2025-03-10
MX2024003947A (es) 2024-04-24
AU2022351990A1 (en) 2024-05-16
IL311581A (en) 2024-05-01
CA3232862A1 (en) 2023-03-30
CL2024000853A1 (es) 2024-10-04
EP4408532A4 (en) 2026-01-21
KR20240068067A (ko) 2024-05-17
US20250002912A1 (en) 2025-01-02
WO2023044545A1 (en) 2023-03-30
CO2024004737A2 (es) 2024-04-29

Similar Documents

Publication Publication Date Title
JP7629404B2 (ja) Ｒｎａ編集オリゴヌクレオチド及びその使用
JP2025003951A (ja) Ｒｎａ編集オリゴヌクレオチド及びその使用
JP2022518731A (ja) Ｒｎａ編集オリゴヌクレオチド及びその使用
JP7714162B2 (ja) Ｍｓｈ３活性に関連するトリヌクレオチドリピート伸長障害の処置のための方法
US20220056455A1 (en) Compositions and methods for the treatment of kcnt1 related disorders
WO2023278410A1 (en) Methods and compositions for adar-mediated editing
US20220307027A1 (en) RNA-Editing Enzyme-Recruiting Oligonucleotides and Uses Thereof
US12485136B2 (en) Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity
JP2024522147A (ja) Ｍｓｈ３活性と関連するヌクレオチドリピート伸長障害の治療方法
AU2020394627B2 (en) Methods for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
WO2025128799A1 (en) Double-stranded rna-editing oligonucleotides and uses thereof
US20250002912A1 (en) Compositions and methods for the treatment of pcdh19 related disorders
US20230041178A1 (en) Methods for the treatment of trinucleotide repeat exapnsion disorders associated with ogg1 activity
CN118922543A (zh) 用于治疗pcdh19相关疾患的组合物和方法
WO2024182578A1 (en) Oligonucleotides for rna editing

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250929